Table 1.
Baseline characteristics of the study population.
| Early transplanted n = 18 | Late transplanted n = 18 | p-value* | |
|---|---|---|---|
| CHARACTERISTICS AT TIME OF TRANSPLANTATION | |||
| Recipient | |||
| Age at transplantation (years) | 54 ± 14 | 50 ± 14 | 0.47 |
| Origin of renal disease, n (%) | 0.61 | ||
| Glomerulonephritis | 1 (6) | 3 (17) | |
| Diabetes mellitus | 1 (6) | 4 (22) | |
| Vascular | 8 (44) | 3 (17) | |
| Genetic | 4 (22) | 3 (17) | |
| Uropathy | 1 (6) | 1 (6) | |
| Undetermined | 3 (17) | 4 (22) | |
| Duration of dialysis (months) | 20 ± 18 | 31 ± 41 | 0.79 |
| DONOR | |||
| Donor age (years) | 53 ± 14 | 46 ± 16 | 0.18 |
| Donor sex, men, n (%) | 12 (67) | 14 (78) | 0.71 |
| Deceased donor, n (%) | 15 (83) | 17 (94) | 0.60 |
| Extended criteria donor, n (%) | 7 (39) | 6 (33) | 1.0 |
| TRANSPLANTATION | |||
| Number of HLA-A, B, C, DR, DQ mismatches | 5.5 ± 2.1 | 5.8 ± 1.6 | 0.59 |
| Combined kidney-pancreas transplantation, n (%) | 0 (0) | 3 (17) | 0.22 |
| Cold ischemia time (min) | 726 ± 479 | 768 ± 427 | 0.90 |
| Delayed graft function, n (%) | 2 (11) | 2 (11) | 1.0 |
| IMMUNOSUPPRESSION | |||
| Induction therapy | |||
| Thymoglobuline, n (%) | 12 (67) | 15 (83) | 0.44 |
| Maintenance regimen | |||
| Tacrolimus, n (%) | 13 (72) | 17 (94) | 0.17 |
| Ciclosporin, n (%) | 5 (28) | 1 (6) | 0.17 |
| mTOR-Inhibitors, n (%) | 3 (17) | 1 (6) | 0.60 |
| Mycophenolate, n (%) | 17 (94) | 16 (89) | 1.0 |
| Azathioprin, n (%) | 0 (0) | 1 (6) | 1.0 |
| Prednisone, n (%) | 11 (61) | 14 (78) | 0.47 |
| CHARACTERISTICS AT TIME OF VACCINATION | |||
| Time elapsed since transplantation (months) | 10 ± 4 | 37 ± 14 | < 0.0001 |
| eGFR (ml/min/1.73m2) | 56 ± 21 | 65 ± 23 | 0.22 |
| Proteinuria >0.5 g/24 h, n (%) | 3 (17) | 4 (22) | 0.91 |
*
Unpaired t-test was used for comparison of continuous variables and Fisher's exact test was used for comparison of proportions.
mTOR, mammalian target of rapamycin; eGFR, estimated glomerular filtration rate.